Chronic Cough Market

Market Overview:

The 7 major chronic cough markets reached a value of US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034.

The chronic cough market has been comprehensively analyzed in IMARC's new report titled "Chronic Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic cough refers to a respiratory tract illness in which cough lasts for an extended period of eight weeks or sometimes much longer. The condition develops in the upper airway of the respiratory system, causing sleep interruption and feelings of fatigue. The common symptoms of this disease include a runny or stuffy nose, sore throat, hoarseness, shortness of breath, wheezing, heartburn or a sour taste in the mouth, frequent throat clearing, etc. Individuals suffering from a chronic cough may also experience postnasal drip, persistent chest pain, coughing up blood, difficulty concentrating at work or school, fractured ribs, headache, and dizziness. Diagnosing this ailment is typically done by evaluating the patient’s clinical features, medical history, and physical examination. The healthcare provider may perform imaging tests, such as chest X-rays and computerized tomography (CT) scans, to detect the lung condition. Additionally, bronchoscopy or rhinoscopy can be used to visualize abnormalities in the nasal passageways, sinuses, and upper airways.

The increasing prevalence of respiratory infections due to high levels of air pollution, chain-smoking, prolonged exposure to dust and chemical fumes, etc., is primarily driving the chronic cough market. Additionally, the rising incidences of several disease-associated risk factors, including asthma, gastroesophageal reflux disease, chronic bronchitis, coronavirus infection, etc., are also bolstering the market growth. Besides this, the escalating usage of the upper endoscopy procedure, which involves the application of a flexible, lighted instrument to monitor the esophagus, stomach, and small intestine and provide disease diagnosis, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, such as antihistamines, bronchodilators, corticosteroids, decongestants, etc., to treat chronic cough by reducing inflammation and opening the airways is acting as another significant growth-inducing factor. In line with this, the growing popularity of over-the-counter cough suppressants, since they can help unclog a stuffy nose by clearing the mucus from the airway, is also augmenting the market growth. Additionally, the emerging application of laparoscopic antireflux surgery (LARS), that primarily aims to reduce acid reflux incidences and impart long-term symptom relief, is positively influencing the market. Furthermore, the rising focus on the development of innovative digital technology to monitor chronic cough conditions, which would aid patients in getting access to the right treatment, is expected to drive the chronic cough market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic cough market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic cough market in any manner.

Recent Developments:

• In December 2023, Merck announced that the United States FDA had issued a Complete Response Letter (CRL) for gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist in development for the management of refractory chronic cough or unexplained chronic cough in adults.
• In November 2023, Trevi Therapeutics, Inc. announced the beginning of its Phase 2a RIVER clinical project to evaluate Haduvio in refractory chronic cough patients. The RIVER trial is a randomized, double-blind, placebo-controlled, two-period crossover research that assesses Haduvio's safety and efficacy in treating refractory chronic cough in participants.
• In June 2023, Aldeyra Therapeutics, Inc. reported favorable Phase 2 clinical trial findings for ADX-629, an experimental novel medication, in patients with chronic cough. The clinical trial showed that ADX-629 significantly reduced cough frequency compared to placebo.

Key Highlights:

• The prevalence estimates for chronic cough varied between 2% to 18%.
• An estimated 10% of adults worldwide with chronic cough report adverse psychosocial and physical impacts such as weariness, depression, and disruptions in social contacts, sleep, and work.
• Chronic cough was most common in smokers, ranging from 27-44%, and was lower in former (7-21%) and nonsmokers (6-15%).
• Chronic cough is more common in men and rises with age.
• Chronic cough was shown to be more common in people who had respiratory, cardiovascular, mental health, chronic pain, or diabetic conditions.

Drugs:

S-600918 is a pharmacological molecule that selectively blocks P2X3 receptors associated with cough reflexes, potentially alleviating refractory or unexplained chronic coughs. A randomized, double-blind, placebo-controlled crossover research included 31 individuals with refractory/unexplained chronic cough lasting at least 6 months. S600918's efficacy and safety were studied after two weeks of once-daily dosing.

Ax-8 is being developed for the treatment of chronic cough. The treatment candidate is delivered via oromucosal and topical routes. It focuses on the transient receptor potential cation channel subfamily M member 8 (TRPM8). The medication candidate is based on TRPM8 technology.

Gefapixant is an orally given, selective P2X3 receptor antagonist under research for the treatment of chronic cough that is resistant or unexplained. P2X3 receptors are located on sensory nerve fibers, primarily C fibers, in the airway lining.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic cough market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic cough market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic cough marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic cough market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic cough market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic cough market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic cough across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic cough by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic cough by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic cough across the seven major markets?
• What is the size of the chronic cough patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic cough?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Cough: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic cough drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic cough market?
• What are the key regulatory events related to the chronic cough market?
• What is the structure of clinical trial landscape by status related to the chronic cough market?
• What is the structure of clinical trial landscape by phase related to the chronic cough market?
• What is the structure of clinical trial landscape by route of administration related to the chronic cough market?